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ABSTRACT
Introduction Mothers with gestational diabetes mellitus 
(GDM) are at increased risk of pregnancy- related 
complications and developing type 2 diabetes after 
delivery. Diet and physical activity- based interventions may 
prevent GDM, but variations in populations, interventions 
and outcomes in primary trials have limited the translation 
of available evidence into practice. We plan to undertake 
an individual participant data (IPD) meta- analysis of 
randomised trials to assess the differential effects and 
cost- effectiveness of diet and physical activity- based 
interventions in preventing GDM and its complications.
Methods The International Weight Management in 
Pregnancy Collaborative Network database is a living 
repository of IPD from randomised trials on diet and 
physical activity in pregnancy identified through a 
systematic literature search. We shall update our existing 
search on MEDLINE, Embase, BIOSIS, LILACS, Pascal, 
Science Citation Index, Cochrane Database of Systematic 
Reviews, Cochrane Central Register of Controlled Trials, 
Database of Abstracts of Reviews of Effects and Health 
Technology Assessment Database without language 
restriction to identify relevant trials until March 2021. 
Primary researchers will be invited to join the Network 
and share their IPD. Trials including women with GDM 
at baseline will be excluded. We shall perform a one 
and two stage random- effect meta- analysis for each 
intervention type (all interventions, diet- based, physical 
activity- based and mixed approach) to obtain summary 
intervention effects on GDM with 95% CIs and summary 
treatment–covariate interactions. Heterogeneity will 
be summarised using I2 and tau2 statistics with 95% 
prediction intervals. Publication and availability bias will 
be assessed by examining small study effects. Study 
quality of included trials will be assessed by the Cochrane 
Risk of Bias tool, and the Grading of Recommendations, 
Assessment, Development and Evaluations approach will 
be used to grade the evidence in the results. A model- 
based economic analysis will be carried out to assess the 
cost- effectiveness of interventions to prevent GDM and its 
complications compared with usual care.
Ethics and dissemination Ethics approval is not required. 
The study is registered on the International Prospective 
Register of Systematic Reviews (CRD42020212884). 
Results will be submitted for publication in peer- reviewed 
journals.
BACKGROUND
Gestational diabetes mellitus (GDM) refers 
to glucose intolerance that is first diagnosed 
in pregnancy.1 GDM affects between 7% 
and 27% of pregnancies globally with varia-
tions in estimates according to the popula-
tion and criteria used for diagnosis.2 During 
Strengths and limitations of this study
 ► The individual participant data (IPD) meta- analysis 
builds on an established global group’s (International 
Weight Management in Pregnancy) living database 
(24 766 women, 58 trials) with the potential to ex-
pand further with additional published data.
 ► Increased power in IPD compared with aggregate 
meta- analysis to determine the differential effects 
of lifestyle interventions on gestational diabetes.
 ► Detailed mapping of the of the intervention compo-
nents will enable translation of the results to clinical 
practice.
 ► Limitations include potential lack of access to new 
data and missingness in available data.
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pregnancy, mothers with GDM are at increased risk of 
pre- eclampsia, caesarean section and preterm delivery; 
their babies are at risk of shoulder dystocia, hyperbiliru-
binaemia, neonatal hypoglycaemia and of being admitted 
to neonatal intensive care.3 GDM is estimated to increase 
the cost of maternity care alone by 34%–95% compared 
with women without GDM.4 5 Women with a history 
of GDM are at 10- fold higher risk of developing type 2 
diabetes mellitus with a cumulative incidence of around 
16%.6 Babies born to women with GDM are also at risk 
of obesity7 and type 2 diabetes8; the long- term compli-
cations in the mother and baby have a significant effect 
on their life expectancy9 and quality of life.10 The UK’s 
National Health Service (NHS) spend on type 2 diabetes 
is projected to increase from £8.8 to over £13 billion per 
year in the next 15 years.11
Despite the publication of over 70 trials to date on the 
effects of lifestyle interventions on gestational diabetes, 
with over £10 million invested, the findings have not been 
translated into clinical practice, guidelines and policy 
frameworks.12–14 Meta- analyses of studies on diet and 
physical activity- based interventions in pregnancy have 
shown a reduction in rates of GDM than usual care, but 
studies varied in population, intervention and outcome 
definitions.14 We also do not know if the beneficial effects 
of diet and physical activity apply to all pregnant women 
or only to subgroups of women with risk factors such as 
high Body Mass Index (BMI), high maternal age, ethnic 
minority origin and low socioeconomic status. The imple-
mentation of lifestyle interventions in a scalable way is 
also hindered by the lack of details about the type, inten-
sity and setting of the effective interventions, and the cost- 
effectiveness of the intervention.
We plan to undertake an individual participant data 
(IPD) meta- analysis of diet and physical activity- based 
interventions to assess the intervention effects on GDM 
and to assess if the effects vary according to maternal 




1. To evaluate the effects of diet and physical activity- 
based lifestyle interventions in pregnancy, across all 
interventions, and for each type of intervention (diet- 
based, physical activity- based and mixed) on gesta-
tional diabetes as defined by the National Institute 
for Health and Care Excellence (NICE) and by study 
authors.
2. To assess the differential effects of interventions ac-
cording to the maternal characteristics (BMI, age, par-
ity, ethnicity and socioeconomic status) on gestational 
diabetes.
Secondary
1. To evaluate the effects of the interventions on critically 
important (1) maternal complications such as hyper-
tensive diseases, caesarean section or preterm birth; 
and (2) offspring complications such as stillbirth, large 
for gestational age or admission to the neonatal unit in 
women with gestational diabetes.
2. To categorise the interventions by core components 
and to undertake network meta- analysis to rank them 
by effectiveness.
3. To assess the effects of interventions for specific other 
definitions of gestational diabetes (WHO, Internation-
al Association of Diabetes and Pregnancy Study Group 
(IADPSG), modified IADPSG, and American Diabetes 
Association (ADA)), and on fasting and 2- hour post- 
prandial glucose levels.
4. To determine the cost- effectiveness of interventions us-
ing decision–analytical modelling.
METHODS/DESIGN
The protocol adheres to Preferred Reporting Items for 
Systematic Review and Meta- Analysis Protocols reporting 
statement15 and has been registered on the International 
Prospective Register of Systematic Reviews with registra-
tion ID CRD42020212884, and our IPD meta- analytical 
approach will follow existing methodological guidelines 
and adhere to the Preferred Reporting Items for System-
atic Reviews and Meta- Analyses IPD reporting statement.16
Patient and public involvement
Patients have been involved with this work throughout and 
have informed design, outcome selection and reporting.
Literature search
We will update the literature search using our existing 
search strategy14 to identify new trials that have been 
published since the completion of our previous review.12 
We will search MEDLINE, Embase, BIOSIS, LILACS, 
Pascal, Science Citation Index, Cochrane Database 
of Systematic Reviews, Cochrane Central Register of 
Controlled Trials, Database of Abstracts of Reviews of 
Effects and Health Technology Assessment Database 
without language restrictions up to March 2021. Two 
independent reviewers will extract data in duplicate.
Establishment of the International Weight Management in 
Pregnancy (i-WIP) group
Our i- WIP collaborative group was established in 2013 
(40 researchers, 16 countries), which brings together 
researchers of primary trials on diet and physical activity 
in pregnancy who have shared IPD from their trials 
towards the collaborative group database, forming the 
largest living global database on diet and physical activity 
interventions in pregnancy. The group is supported by 
the WHO, and to date, we have access to 24 766 women 
from 58 studies (online supplemental appendix 1).
Inclusion and exclusion criteria
Trials with random allocation (individual or cluster) on 
diet and physical activity- based interventions in preg-
nancy compared with standard antenatal care will be 
eligible for inclusion. Any trials that included women 
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at baseline with gestational diabetes will be excluded. 
We will only include pregnant women with a BMI of 
≥18.5 kg/m2 in early pregnancy to exclude women who 
are underweight. We will evaluate three main interven-
tions for gestational diabetes prevention in pregnancy: 
diet- based, physical activity- based, and mixed approach 
interventions incorporating diet and physical activity 
components underpinned by behavioural approach. 
Diet- based interventions include various dietary patterns 
such as Mediterranean- style diet, low calorie diet and low 
glycaemic index diet, which are offered by clinicians, 
dietitians, physiotherapists, or commercial companies in 
both primary and secondary care settings. The interven-
tions are delivered using vehicles such as print or digital 
media, phone, face- to- face meetings in either one- on- one 
or group sessions, and are commenced at various time 
points in pregnancy and delivered in an intense regi-
mented or pragmatic manner. The physical activity- based 
interventions involved moderate exercise such as dance- 
based exercise programmes, water- based physical activity, 
stationery cycling, light intensity resistance training or 
enhanced routine daily activity, including walking. The 
mixed approach includes both diet and physical activity. 
Studies assessing other weight loss interventions such as 
pharmacotherapy or surgery will not be included.
We have previously identified the various interventions 
for inclusion in the IPD meta- analysis.17 18 We will map the 
components and taxonomy of the interventions against 
the clinical outcomes.
Outcome measures
The primary outcomes are GDM as defined by NICE19 
or by any established criteria. Our secondary outcomes 
include other definitions of GDM (IADPSG,20 modi-
fied IADPSG,21 22 WHO23 and ADA criteria24), maternal 
and offspring complications such as hypertensive disor-
ders, including pre- eclampsia, preterm birth, caesarean 
section and need for pharmacological therapy for 
hyperglycaemia, shoulder dystocia, respiratory distress 
syndrome, neonatal hypoglycaemia, stillbirth, neonatal 
death, perinatal death, Apgar score at 1 and 5 min, birth 
weight, gestational age at birth, small/large for gesta-
tional age and admission to the neonatal intensive care 
unit (table 1). Subgroup analysis will explore whether a 
woman’s BMI, age, parity, ethnicity and socioeconomic 
status modify the intervention effect.
Study quality assessment and data collection
The existing i- WIP dataset will be expanded to include 
new studies. We will use our previously peer- reviewed 
Table 1 Structured research question
Question 
components
Population Pregnant women with a BMI of ≥18.5 kg/m2 in early pregnancy
Interventions Diet- based
  Physical activity- based
  Mixed approach: diet and/or physical activity with behavioural component
Outcomes Primary outcomes
  Gestational diabetes defined as per 2015 NICE criteria (fasting glucose 5.6 mmol/L or above, and 2- hour 
glucose 7.8 mmol/L or above after a 75 g oral glucose tolerance test)19 or GDM as defined within the study 
by established criteria
Differential effects of interventions across subgroups based on maternal BMI, age, parity, ethnicity and 
socioeconomic status
  Secondary outcomes
  Gestational diabetes with maternal and /or offspring complications
  Maternal: hypertensive diseases including pre- eclampsia, caesarean section, preterm birth and need for 
pharmacological therapy for hyperglycaemia
  Offspring: shoulder dystocia, respiratory distress syndrome, neonatal hypoglycaemia, stillbirth, neonatal 
death, perinatal death, Apgar score at 1 and 5 min, birth weight, gestational age at birth, small/large for 
gestational age and admission to the neonatal unit
Categorisation of the interventions by core components and undertake network meta- analysis to rank 
them by effectiveness
  Gestational diabetes as defined specifically using the IADPSG,20 modified IADPSG,21 22 WHO23 and ADA24
Cost- effectiveness of interventions using decision–analytical modelling
Study design of 
included studies
Randomised trials
ADA, American Diabetes Association; BMI, Body Mass Index; GDM, gestational diabetes mellitus; IADPSG, International Association of 
Diabetes in Pregnancy Study Group; NICE, National Institute for Health and Care Excellence.
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robust methods to assess the quality of the new studies 
and to extract and format the relevant data.12 We will 
use the risk of bias tool developed by the Cochrane 
Collaboration to score the quality of (the IPD from) 
each study.25 This will be based on study character-
istics and supplemented with information from IPD 
when provided. Sensitivity analyses will examine the 
robustness of statistical and clinical conclusions to 
inform the inclusion or exclusion of trials deemed to 
be at high risk of bias.
We will extract additional data from existing and 
new studies where possible on the diagnostic criteria 
and oral glucose tolerance test (OGTT) values used 
to diagnose gestational diabetes. We will also extract 
relevant information on the intervention components, 
and offspring and maternal complications. We will 
follow the established, tested and trialled procedures 
used for data harmonisation in the i- WIP database.26 
This will facilitate smooth and timely execution of the 
most time- consuming stage of the study, that is, data 
cleaning and its harmonisation.
Sample size consideration
Formal sample size calculations are not usually under-
taken for meta- analyses. Brookes et al note that about 
four times the size of a single trial is required to detect 
an interaction with the same size as the overall treat-
ment effect.27 We currently have access to the shared 
data for 24 766 women (58 studies). The sample size 
has the potential to be increased further to 27 538 
women (71 studies) and beyond, depending on 
decisions to share data by other identified studies, 
and by the number of new studies published up to 
March 2021. We have undertaken a simulation- based 
approach to calculate the power of estimating genuine 
treatment–covariate interactions in our planned IPD 
meta- analysis, conditional on the number of trials, 
number of participants available in each trial and the 
covariate characteristics (eg, proportion of Cauca-
sian subjects, mean and SD of BMI) while allowing 
for between- study heterogeneity in the treatment 
effect and the control group risk.28 29 We calculated 
the power to detect a particular treatment–covariate 
interaction effect size in the subset of trials that report 
each covariate of interest (BMI, age, ethnicity, parity 
and socioeconomic status). Table 2 shows the power 
estimates, assuming an interaction between covariate 
and treatment effect corresponding to 30% (OR 0.70) 
and 25% reductions in gestational diabetes (OR 0.75) 
Table 2 Estimated power by simulation based on the IPD currently available in the i- WIP database*
Covariate (subgroup) of interest
Assuming all 71 trials 
identified so far provide their 
IPD




















Assuming an interaction between covariate and treatment effect that corresponds to an OR of 0.70
BMI Obese versus non- obese 70 (27 722) 99.0 56 (24 443) 97.6
Age Continuous assuming 
linear trend
69 (27 422) 79.1 55 (24 143) 78.4
Ethnicity Caucasian versus non- 
Caucasian
48 (21 958) 93.4 39 (19 394) 90.4
Parity Nulliparous versus 
multiparous
59 (22 253) 95.4 48 (19 718) 93.4
Socioeconomic status High versus low 50 (21 136) 95.0 41 (19 426) 90.0
Assuming an interaction between covariate and treatment effect that corresponds to an OR of 0.75
BMI Obese versus non- obese 70 (27 722) 92.8 56 (24 443) 89.2
Age Continuous assuming 
linear trend
69 (27 422) 72.4 55 (24 143) 65.2
Ethnicity Caucasian versus non- 
Caucasian
48 (21 958) 79.8 39 (19 394) 74.4
Parity Nulliparous versus 
multiparous
59 (22 253) 85.8 48 (19 718) 77.2
Socioeconomic status High versus low 50 (21 136) 85.4 41 (19 426) 83.2
*Assuming baseline risk of gestational diabetes is 11% on average, varying from 2% to 43% according to trial characteristics.
BMI, Body Mass Index; IPD, individual participant data; i- WIP, International Weight Management in Pregnancy.
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across covariate (sub)groups, using the sample size of 
available IPD (58 trials), and also if all 71 trials shared 
their IPD. We expect to have sufficient events for the 
overall effect, and for most of the secondary outcomes 
with 5291 caesarean sections, 1154 preterm births; 
1769 hypertensive diseases; 2483 large- for- gestational 
age babies; and 1420 babies admitted to the neonatal 
unit.
Data analysis
Overall effect and sub types of intervention
The effectiveness of the diet and physical activity- based 
interventions will be assessed using IPD meta- analytical 
framework.30 GDM as defined by NICE19 or GDM as 
defined within the study by established criteria will be 
the main outcome. For each intervention type (all inter-
ventions, diet- based, physical activity- based and mixed 
approach), we will perform one- stage and two- stage 
IPD random- effect meta- analyses to obtain the pooled 
(summary) intervention effect on GDM via restricted 
maximum likelihood (ML) estimation or, for non- 
continuous outcomes, ML estimation. One- stage models 
will use intercepts stratified by study to account for clus-
tering, and covariates will be centred to improve esti-
mation.31 CIs will be inflated to account for uncertainty 
in variance estimates (eg, using Hartung- Knapp and 
Kenward- Roger corrections for two- stage and one- stage 
approaches, respectively).32 All approaches will adjust 
for a few key prognostic factors available in all the IPD 
studies, which is anticipated to be age and BMI, to ensure 
conditional treatment effects are summarised. Adjust-
ment factors will be stratified by study.
One- stage and two- stage analyses usually give similar 
results, and so any discrepancies will be resolved.33 We will 
use a random- effect meta- analysis approach, which allows 
for between- study heterogeneity in intervention effect, 
which is anticipated. Heterogeneity will be summarised 
using the I- squared statistic (which provides the propor-
tion of total variability that is due to between- study 
heterogeneity) and the estimated between- study vari-
ance (‘tau2’). To reveal the impact of heterogeneity more 
clearly, we will also calculate a 95% prediction interval 
for the intervention effect when applied in an individual 
clinical setting. The aforementioned analyses will also be 
undertaken for secondary outcomes, and GDM will be 
defined using other specific criteria such as IADPSG,20 
modified IADPSG,21 22 WHO23 and ADA.24
Differential effect by subgroups (treatment–covariate interactions)
We will examine whether a woman’s BMI, age, parity, 
ethnicity and socioeconomic status modify intervention 
effect. This will be undertaken by extending the two- stage 
and one- stage meta- analysis frameworks to include and 
then summarise treatment–covariate interaction terms, 
which provides the change in intervention effect for a 
1- unit change in the covariate. We will always adjust for 
the prognostic effects of the covariate, in addition to 
others listed previously (ie, age and BMI). Ecological bias 
due to study- level confounding will be avoided using the 
deft approaches of Fisher et al34
Continuous variables will be kept as continuous to avoid 
arbitrary dichotomisation, and non- linear relationships 
and interactions will be modelled using restricted cubic 
splines and multivariate IPD meta- analysis.35 Subgroup 
analyses, if not carefully planned, can lead to misleading 
results, for example, due to the play of chance with 
multiple testing.25 Thus, caution will be used in interpre-
tation of the collective set of subgroup results. However, 
our IPD meta- analysis will increase the power (often 
>80%) to detect genuine subgroup effects (treatment–
covariate interactions) and will also allow us to examine 
if there is consistency in the subgroup effect from study 
to study, rather than being a chance finding in a single 
study, for example.
Examining potential sources of bias
Small study effects (potential publication bias) will 
be investigated through the construction of contour- 
enhanced funnel plots and appropriate statistical tests. 
To examine the impact of studies with unavailable IPD, 
we will extract (where available) appropriate aggregate 
study- level data (eg, interaction estimates) and incor-
porate them alongside the IPD using two- stage IPD 
random- effect meta- analysis.36 Sensitivity analyses will be 
undertaken that exclude studies not at low risk of bias, 
to ascertain if conclusions change when all studies are 
included. We will use the Grading of Recommendations, 
Assessment, Development and Evaluations approach to 
grade the evidence in our IPD meta- analysis.37
Dealing with missing variables
A range of strategies will be considered for dealing with 
missing data. In particular, multiple imputation will be 
used to impute partially missing variables within each 
study separately, under a missing at random assump-
tion. If there are systematically missing variables then, 
where considered plausible, these will also be imputed by 
borrowing information across studies while allowing for 
heterogeneity and clustering in a multilevel imputation 
model.38
Decision–analytical modelling
We will develop a decision–analytical simulation model 
to assess the cost- effectiveness of interventions involving 
diet and physical activity to prevent GDM and complica-
tions compared with usual care (control). The model will 
be developed using TreeAge Pro 2017 software (TreeAge 
Software, Williamstown, Massachusetts, USA). The struc-
ture and pathways will be informed by the data and trials 
included in the IPD meta- analysis, clinical input, NICE 
guidelines on the management of women in pregnancy 
and the approaches adopted in our previous model- based 
economic evaluations.12 The model will include all the 
potential pathways that could be followed by the women 
who will enter the model at the point of randomisation, 
to receive the intervention or care as usual.
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For the intervention effect, data from the IPD meta- 
analysis will estimate pooled effect ORs for the develop-
ment of GDM. The baseline risk for the usual care group 
will be calculated on the pooled data for the control 
groups included in the trials. Maternal outcomes will not 
be considered where they are already observed at base-
line. The estimated risk of maternal death will be from 
appropriate recent sources.39 40 NHS reference costs will 
provide much of the required cost data, and additional 
secondary sources will be interrogated. Costs from all 
secondary sources will be inflated as appropriate using 
the hospital and community health services pay and 
price index.41 Costs presented in foreign currency will be 
converted to UK pounds using historical annual average 
rates42 and then inflated to current prices. Estimates of 
the cost of weight management interventions and ante-
natal and postnatal care costs will be based on results of 
our systematic review of economic evaluations of weight 
management interventions in pregnancy.12
The main analysis will compare costs and outcomes for 
a hypothetical cohort of 10 000 pregnant women, based 
on the results of the IPD meta- analysis for all women. For 
secondary analysis, we will compare costs and outcomes 
for subgroups of women based on their characteristics, 
such as BMI, age, ethnicity, parity and socioeconomic 
status, to allow exploration of whether a lifestyle inter-
vention in selective subgroups of women is a more cost- 
effective strategy compared with care as usual. For all 
analyses, the relative cost- effectiveness of the intervention 
will be evaluated using effect size estimates from the IPD 
meta- analysis. An incremental approach will be adopted 
with a focus on the additional costs and benefits asso-
ciated with a move from care as usual to diet and life-
style interventions to manage weight gain in pregnancy. 
The results will be reported in terms of an incremental 
cost- effectiveness ratio of cost per unit of benefit gained, 
measured in natural clinical outcomes. The analysis will 
be conducted from the perspective of the health service 
(NHS), and only direct health service will be included. 
The time horizon adopted for both the primary and 
secondary analyses will be the start of pregnancy until 
the mother and infant are discharged from the hospital 
following the birth. Missing data will be addressed in the 
IPD meta- analysis.
We will perform Monte Carlo simulation to evaluate the 
effect of parameter uncertainty for probabilistic sensitivity 
analysis. We will summarise the results graphically using a 
cost- effectiveness acceptability curve to show the uncer-
tainty surrounding the cost- effectiveness of the inter-
vention for a range of thresholds for cost- effectiveness. 
A value of information analysis will be conducted to 
estimate the expected costs of uncertainty. Addition-
ally, we will perform deterministic sensitivity analyses to 
check the robustness of the model.43 The expected cost 
of uncertainty is calculated by estimating the probability 
of making a wrong decision based on existing evidence, 
and the consequences of this wrong decision. The 
expected value of perfect information (EVPI) estimates 
the difference between the expected value of the decision 
made with perfect information and the decision made 
based on existing evidence. EVPI was calculated based on 
the methods described in Claxton and Posnett43. Among 
the many deterministic analyses to be explored, the effect 
of considering a longer time horizon will also be included.
DISCUSSION
We have previously shown in our IPD meta- analysis that 
women of all BMI groups could benefit from specific 
advice on diet and physical activity for weight gain in 
pregnancy. Findings from this proposal will show whether 
this benefit extends to gestational diabetes and other 
maternal or neonatal outcomes. Identification of the 
subset of women who would benefit from lifestyle inter-
ventions in pregnancy to prevent gestational diabetes 
will allow us to evaluate whether targeted management 
of these groups of women will improve their pregnancy 
outcomes. We will also be able to evaluate whether there 
is any differential effect according to the individual 
components of the intervention on pregnancy outcomes, 
which is required to provide a detailed recommendation. 
Our detailed protocol is produced in line with established 
guidance15 that provides an in depth a priori overview of 
our IPD meta- analysis, which is intended to deliver imple-
mentable findings that can be translated into clinical 
practice and improve the care of women at risk of GDM 
and its associated complications.
The Delphi survey of our international collaborative 
group ranked GDM to be critically important to the care 
of pregnant women.44 In our previous IPD meta- analysis, 
we observed a statistically non- significant reduction in the 
rate of GDM with lifestyle interventions in our previous 
IPD meta- analysis (OR 0.89, 95% CI 0.72 to 1.10).14 
However, addition of aggregate data from studies that 
did not contribute IPD resulted in a stronger evidence of 
a significant reduction in gestational diabetes, but ques-
tions on effectiveness of such interventions on gestational 
diabetes remained due to the inherent bias with this 
approach.12 14 The recent Cochrane review’s aggregate 
meta- analysis showed similar findings13 and reported the 
quality of evidence to be low due to variations in the defi-
nitions, small sample sizes with imprecise estimates and 
statistical heterogeneity. However, the aforementioned 
reviews did not include the recently published large trials 
indicating potential beneficial effects of lifestyle inter-
vention on gestational diabetes: the ESTEEM trial (1230 
women, 2019) on Mediterranean diet reducing gesta-
tional diabetes, a component of the composite primary 
outcome, by 35%,45 and the St Carlos trial (800 women), 
showing a similar reduction in gestational diabetes but 
with lower power.46
There are several other limitations with current 
evidence. First, the potential for lifestyle interventions to 
prevent GDM was only shown when aggregate and IPD 
data was combined and not in previous IPD meta- analysis 
alone. Second, whether the effects of diet and physical 
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activity interventions would apply equally to all pregnant 
women or only to those at greater potential risk such 
as those with obesity, high maternal age or those from 
ethnic minorities origins is unknown. Third, the lack of 
detail about the interventions (including type, intensity 
and setting), as well as the associated costs of the inter-
ventions, limits delivery. Fourth, previous meta- analyses 
have been reliant on the definitions of GDM used in 
the original manuscript. Fifthly, the impact on clinically 
important outcomes, including complications of GDM, is 
not known.
We expect our proposed IPD meta- analysis to have 
additional power to identify differential effects across 
different risk groups of women on GDM risk as well 
as the components of the interventions in different 
patient groups that show clear benefits to prevent GDM. 
Currently, the key barriers to implementation of effective 
interventions to prevent gestational diabetes include lack 
of robust evidence on the effectiveness, lack of clarity 
about key components of complex diet and physical 
activity interventions, lack of information on costs asso-
ciated with interventions and lack of information on who 
should be targeted. Our IPD meta- analysis will answer 
these questions. We have so far mapped the components 
of the interventions using the Intervention Description 
and Replication framework17 and categorised by type 
(diet, physical activity and mixed), frequency, inten-
sity (high, medium and low), duration (prepregnancy, 
first trimester and second trimester), delivery (face- to- 
face or e- health, individual and group sessions), setting 
(primary and secondary care), theoretical underpinning 
(eg, problem solving and action planning) and resources 
used. We also used a 96- item framework18 to identify the 
behavioural change components applied within interven-
tions. This work is crucial to our proposed plan to identify 
those components of the intervention that are most effec-
tive in preventing gestational diabetes.
Additionally, the incorporation of the raw data in the 
IPD meta- analysis will allow us to assess the impact of the 
interventions on GDM as defined by different criteria, 
including NICE,19 rather than a reliance on the defini-
tions used by the original reporting paper. Following 
extensive collaboration with members of the i- WIP 
consortium, we have obtained additional data on all avail-
able OGTT values, which will be used in the proposed 
i- WIP GDM project. It is further anticipated that by using 
raw data, the breadth of outcomes that can be analysed 
will increase compared with aggregate meta- analysis; 
for example, papers may not have reported preterm 
delivery, yet raw data will incorporate the gestational age 
at delivery, allowing this outcome to be analysed.
Mutual trust and common research goal are the corner-
stones of our i- WIP collaborative group. We have robust 
operating procedures in place for data access, publication 
and data sharing. The collaborative efforts need to take 
into account the equity challenges within systems, such 
as low socioeconomic status, deprivation and ethnicity, 
which are linked to variations in gestational diabetes 
rates and affect access to interventions. Organisational 
or delivery system- wide challenges depend on the setting, 
type of intervention, mode of delivery (digital, groups 
and individual- based) and workforce skills. An additional 
challenge is to rebalance the ongoing local, regional 
and national efforts and initiatives to tackle diabetes and 
obesity, with maternity transformation strategies focusing 
on improved maternal and child health, alongside effi-
cient workforce skills development.
We will robustly address these by first identifying if the 
interventions need to be targeted to these groups and 
then by working with policymakers and patient and public 
involvement groups to identify ways to implement and 
reach communities that have the most need. Our work 
will directly feed into the ongoing efforts of NHS England 
to identify effective lifestyle interventions to prevent 
maternal obesity and complications like gestational 
diabetes. If specific subgroups of women were found 
to benefit the most, this can lead to re- organisation or 
commencement of new services in primary and secondary 
care. For for example, if women with obesity were found 
to benefit the most, current weight management services 
will need to incorporate the specific components of the 
intervention found to be most effective in preventing 
gestational diabetes. Furthermore, with increasing access 
to digital interventions, these findings could lead to the 
delivery of the intervention to virtual target groups. The 
cost- effectiveness findings and details on the type of effec-
tive intervention are key factors in implementation.
ETHICS AND DISSEMINATION
This is an evidence synthesis project involving meta- 
analysis of anonymised datasets. No further ethical 
considerations or approvals are needed. Guidance on 
participant data storage and management will be adhered 
to. The results will be published in peer- reviewed jour-
nals, shared in policy briefings to NHS England Directors, 
UK Chief Medical Officers, NICE Guideline leads, NHS 
providers and local authorities. We will also make our 
findings available in accessible formats to patient groups 
and relevant charities.
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